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General Information 
1H NMR spectra were recorded on a Bruker AV-400 spectrometer at 400 MHz. Chemical shifts 
(δ) of NMR are reported in parts per million (ppm) units relative to residual undeuterated solvent. The 
following abbreviations were used to describe peak splitting patterns when appropriate: s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet), br s (broad signal), dd (doublet of doublets). Coupling 
constants (J) are expressed in hertz unit (Hz). High resolution mass spectra (HRMS) were obtained on 
a Q-STAR Elite ESI-LC-MS/MS Spectrometer. The purity of compounds was determined by 
reverse-phase high performance liquid chromatography (HPLC) analysis to be over 95% (>95%). 
HPLC instrument: Dionex Summit HPLC (Column: Diamonsil C18, 5.0 μm, 4.6× 250 mm (Dikma 
Technologies); detector: PDA-100 photodiode array; injector: ASI-100 autoinjector; pump: p-680A). 
Elution: MeOH in water; flow rate: 1.0 mL/min. Elemental analysis was used to determine the purity 
of the described compounds (SunYat-sen University, China). Where molecular formulas are given, 
elemental compositions were found to be within 0.4% of the theoretical values. The purities of the 
compounds were confirmed over 95% (≥ 95%). All reagents were purchased from suppliers without 
further purification. 
Synthesis of 3a-3h 
The synthesis of designed compounds 3 was outlined in Scheme S1. Briefly, a direct nucleophilic 
coupling of commercially available ethyl 2, 4-dichloropyrimidine- 5-carboxylate (4) with tert-butyl 
3-aminophenylcarbamate (5) produced ethyl 4-((3-((tert-butoxycarbonyl)amino)phenyl)amino)-2-chlor 
-opyrimidine-5-carboxylate (6) in 82% yield. Hydrolysis of compound 6 with 1 M NaOH in a 
H2O-THF mixed solution yielded the carboxylic acid (7). The condensation of 7 and 8a-8e in the 
presence of HATU and DIPEA in dry DCM gave the intermediates 9a-9e, respectively. Compounds 
9a-9e were coupled with different substituted anilines via nucleophilic substitution and followed by 
deprotection with 50% trifluoroacetic acid in DCM to yield the key precursors 10a-10h. The 
conformation-constrained EGFR inhibitors 3a–3h were finally obtained by acryloylation of 10a-10h 
with acryloyl chloride.  
Scheme S1. Chemical synthesis of compounds 3a-3h. 
S3 
 
N
NCl
O
Cl
O
N
NCl
O
NH
O
NHBoc
N
NCl
OH
NH
O
NHBoc
N
NO
N
N
O
NHBoc
N
N
N
NN
NH2
NHBoc
N
NHN
N
N
O
NH2
N
N
NHN
N
N
O
NH
N
N
N
HS
O
n
n n n
N
N
HS
N
NO
N
N
O
NHBoc
N
N
N
NN
N
NHN
N
N
NH2
N
N
NHN
N
N
O
NH
N
O
O
N
N
HCl
N
NO
N
N
O
NHBoc
N
N
N
NN
N
NHN
N
N
NH2
N
N
NHN
N
N
O
NH
N
O
O
O
N
N
O
N
N
R1
R2
R1
R2
N
O
N
4 5 7
9a-c
9d
9e
10a-c
10d, 10f-h
10e
3a-c
DIPEA, CH3CN 1M NaOH, THF
HATU, DIPEA, DCM, rt
6
3d,3f-h
N
O
N 3e
7
7
8a-c
8d
8e
a, n=1
b, n=2
c, n=3
10d, 3d.R1 = MeO; R2 =4-methylpiperazin-1-yl
10f, 3f. R1 = MeO; R2 = morpholino
10g, 3g.R1 = MeO; R2 = 4-(dimethylamino) piperidin-1-yl
10h, 3h. R1 = EtO; R2 =4-methylpiperazin-1-yl
80oC 50oC
(1) K2CO3, t-BuOH
RNH2, 100oC
(2) TFA, DCM, rt
acryloyl chloride
DIPEA, DCM
0oC-rt
HATU, DIPEA, DCM, rt
(1) K2CO3, t-BuOH
RNH2, 100oC
(2) TFA, DCM, rt
acryloyl chloride
DIPEA, DCM
0oC-rt
HATU, DIPEA, DCM, rt
(1) K2CO3, t-BuOH
RNH2, 110oC
(2) TFA, DCM, rt
acryloyl chloride
DIPEA, DCM
0oC-rt
The synthetic procedures and characterization data of 3a-3h 
N
NCl
O
NH
O
NHBoc
6  
Ethyl 4-((3-((tert-butoxycarbonyl)amino)phenyl)amino)-2-chloropyrimidine -5-carboxylate(6)  
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A mixture of ethyl 2, 4-dichlo-ropyrimidine-5-carboxylate (22.1g, 100mmol), tert-butyl 
(3-aminophenyl)carbamate (20.8g, 100mmol), and diisopropyl-ethyl amine(17.4 mL, 100mmol) in 
CH3CN (500 mL) was refluxed for 2 hrs.[1] After being cooled to room temperature, the precipitate 
was filtered to give 9 as a white solid (32.2g, 82%). 1H NMR (400Hz, CDCl3) δ 10.44 (s, 1H), 8.82 (s, 
1H), 7.79 (s, 1H), 7.37 (d, J = 7.6 Hz , 1H), 7.29 (t, J = 8.0Hz, 1H,), 7.18 (d, J=8.0Hz, 1H,), 6.55 (s, 
1H), 4.45 (q, J=7.2Hz, 2H), 1.53 (s, 9H), 1.43 (t, J=7.2Hz, 3H). 
 
4-((3-((tert-butoxycarbonyl)amino)phenyl)amino)-2-chloropyrimidine-5-carboxylic acid (7) 
A solution of 6 (3.92g, 10mmol) in THF and 1 M NaOH (20mL, 20mmol) was stirred at 50 oC 
for 4 hrs, then the solvent was partly removed under reduced pressure. The solution was acidified with 
1 M HCl (25mL, 25mmol) and cooled to give a solid, which was collected by filtration and dried in a 
vacuum oven to give 7 as a white solid (3.57g, 98%). 1H NMR (400Hz, DMSO- d6) δ 10.56 (s, 1H), 
9.47 (s, 1H), 8.77 (s, 1H), 7.68 (t, J=2.0Hz, 1H), 7.39 (d, J=8.0Hz, 1H), 7.28 (t, J=8.0Hz, 1H), 7.24 (d, 
J=8.4Hz, 1H), 1.48 (s, 9H). 
 
tert-butyl(3-(2-((3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)oxy)-5-oxo-7,8-dihydroimidazo[1,2-a]pyri
mido[4,5-d]pyrimidin-10(5H)-yl)phenyl)carbamate (9a) 
A mixture of 7 (91.2mg, 0.178mmol), HATU (190.11mg, 0.356mmol) and diisopropyl-ethyl 
amine (0.13ml, 0.534mmol) in DCM (2 mL) was stirred for 0.5 hr at room temperature, then 
2-(methylthio)-4,5-dihydro-1H-imidazole (20.68mg, 0.178mmol) was added to the mixture. The 
reaction mixture was stirred for 24 hrs at room temperature before being partitioned between water 
and DCM. The organic layer was separated, dried over MgSO4 and concentrated, and the crude 
product was purified by flash silica gel chromatography with dichloromethane/methanol (200/1 to 
150/1, v/v) to give 9a as a white solid (75mg, 58%). 1H NMR (400Hz, DMSO- d6) δ 9.47 (s, 1H), 8.85 
(s, 1H), 8.68(dd, J=1.2Hz, 4.4Hz, 1H) , 8.56 (dd, J=0.8Hz, 8.0Hz, 1H), 7.56 (dd, J=4.4Hz, 8Hz, 1H), 
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7.37 (s, 1H), 7.23 (d, J=8.4Hz, 1H) 7.09 (t. J=8.0Hz, 1H) , 6.65 (d, J=8.0Hz, 1H), 3.97 (t, J=8.8Hz, 
2H), 3.72 (t, J=8.8Hz, 2H), 1.51 (s,9H). 
 
10-(3-aminophenyl)-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-7,8-dihydroimidaz
o[1,2-a]pyrimido[4,5-d]pyrimidin-5(10H)-one (10a) 
To a solution of compound 9a (257mg, 0.5mmol) in tert-Butanol (5 mL) were added 
2-methoxy-4-(4-methylpiper azin-1-yl)aniline (110.6mg, 0.5 mmol) and potassium carbonate 
(207.3mg, 1.5mmol). The reaction mixture was stirred for 6 hrs at 100 ° C in a sealed tube，then the 
solvent was removed under reduced pressure. The residue was partitioned between water and 
dichloromethane. The organic layer was washed with brine, dried over MgSO4, and concentrated to 
give the crude product which was used without further purification.  
To a mixture of the crude product in dichloromethane (2 mL) was added trifluoroaceticacid (TFA, 
2mL). The reaction mixture was stirred overnight at room temperature. The solvent was removed 
under reduced pressure, and neutralized the residue by slow addition of saturated NaHCO3. The 
precipitate formed was collected by filtration and washed with water. The resulting crude product was 
purified by silica gel chromatography with dichloromethane/methanol (60/1 to 30/1, v/v) to give 10a 
as a yellow solid (174.8mg, 70%). 1H NMR (400Hz, CDCl3) δ 8.80 (s, 1H), 7.96(s, 1H), 7.55(d, 
J=8.8Hz, 1H), 7.35(t, J=8.0Hz, 1H), 6.85(d, J=7.2Hz, 1H), 6.76(d, J=7.6Hz, 1H), 6.67(s, 1H), 6.44(s, 
1H), 6.14(d, J=8.4Hz, 1H), 4.12(t, J=8.8Hz, 2H), 3.92(t, J=8.8Hz, 2H), 3.82(s, 3H), 3.16(m, 4H), 
2.67(m, 4H), 2.42(s, 3H). 
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N-(3-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxo-7,8-dihydroimidazo[1,2-a]p
yrimido[4,5-d]pyrimidin-10(5H)-yl)phenyl)acrylamide (3a) 
Acryloyl chloride (24 μ L, 0.30 mmol) was added dropwise to a mixture of 10a (100mg, 
0.2mmol) and diisopropylethylamine (64 μL, 0.40 mmol) in dichloromethane (2 m L) at 0 oC, and 
then warmed to room temperature. The reaction mixture was stirred for 2 hrs. n-Hexane(3 mL) was 
then added to the mixture. The precipitate formed was collected by filtration and purified by silica gel 
chromatography with dichloromethane/methanol (60/1 to 30/1, v/v) to give 3a as a yellow solid 
(71.9mg, 65%). 1H NMR (400Hz, DMSO- d6) δ 10.35 (s, 1H), 8.16 (s, 1H), 8.37 (brs, 1H), 7.83 (brs, 
1H),  7.70 (s, 1H), 7.47 (t, J=8.0Hz, 1H), 7.21 (d, J=8.8Hz, 1H), 7.12 (d, J=8.0Hz, 1H) 6.51 (s, 1H), 
6.48 (dd, J=10.0Hz, 16.8Hz, 1H), 6.28 (dd, J=2.0Hz, 16.8Hz, 1H), 5.95 (br s, 1H), 5.78 (dd, J=2.0Hz, 
10.0Hz, 1H), 3,97 (t, J=8.4Hz, 2H), 3.71-3.75 (m, 5H), 3.05 (m, 4H), 2.26 (s, 3H). HRMS (ESI): exact 
mass calcd for C29H31N9O3 [M + H] +, 554.2623, found 554.2616, HPLC analysis: 85:15 
methanol−water, 5.16 min, 98.6%. 
Compound 9b-9d was synthesized from 7 and different aniline (8b-8d) with similar procedures 
to that of 9a. 
Compound 10b-10d, 10f-10h was synthesized from 9b-9d with similar procedures to that of 10a. 
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N-(3-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxo-8,9-dihydro-5H-dipyrimido
[1,2-a:4',5'-d]pyrimidin-11(7H)-yl)phenyl)acrylamide(3b) 
Compound 3b was synthesized from 10b with similar procedures to that of 3a. 1H NMR (400Hz, 
DMSO- d6) δ 10.31(s, 1H), 8.64(s, 1H), 8.20(s, 1H), 7.85(s, 1H), 7.54(s, 1H), 7.44(t, J=8.0Hz, 1H), 
7.16(d, J=8.8Hz, 1H), 7.00(d, J=8.0Hz, 1H), 6.49(s, 1H), 6.46(dd, J=10.0, 16.8Hz, 1H), 6.27(dd, 
J=2.0, 16.8Hz, 1H), 5.93(br s, 1H), 5.77(dd, J=10.0, 2.0Hz, 1H), 3.86(m, 2H), 3.76(s, 3H), 3.02(m, 
4H), 2.42(t, J=4.4Hz, 4H), 2.22(s, 3H), 1.80(m, 2H). HRMS (ESI): exact mass calcd for C30H33N9O3 
[M + H] +, 568.2779, found 568.2771. HPLC analysis: 85:15 methanol−water, 6.29 min, 99.2%. 
 
N-(3-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxo-7,8,9,10-tetrahydropyrimid
o[4',5':4,5]pyrimido[1,2-a][1,3]diazepin-12(5H)-yl)phenyl)acrylamide (3c) 
Compound 3c was synthesized from 10c with similar procedures to that of 3a. 1H NMR (400Hz, 
DMSO- d6) δ 10.29 (s,1H), 8.61 (s, 1H), 8.18 (s, 1H), 7.85 (s, 1H), 7.50 (s, 1H), 7.42 (t, J=8.0Hz, 1H), 
7.17 (d, J=8.8Hz, 1H), 6.99 (d, J=8.4Hz, 1H), 6.50 (s, 1H), 6.46 (dd, J=10.0Hz, 17.2Hz, 1H), 6.27 (dd, 
J=2.0Hz, 17.2Hz, 1H), 5.94 (br s, 1H), 5.77 (dd, J=2.0Hz, 10.0Hz, 1H), 4.09 (m, 2H), 3.76 (s, 3H), 
3,55 (m, 2H), 3.02 (m, 4H), 2.42(m, 2H), 2.22 (s, 3H), 1.84-1.89 (m, 4H). HRMS (ESI): exact mass 
calcd for C31H35N9O3 [M + H] +, 582.2936, found 582.2930. HPLC analysis: 80:20 methanol−water, 
8.54 min, 97.8%. 
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N-(3-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxoimidazo[1,2-a]pyrimido[4,5-
d]pyrimidin-10(5H)-yl)phenyl)acrylamide (3d) 
Compound 3d was synthesized from 10d with similar procedures to that of 3a. 1H NMR (400Hz, 
DMSO- d6) δ 10.41(s, 1H), 8.99-9.07(m, 1H), 8.70(s, 1H), 7.90(s, 1H), 7.83(s, 1H), 7.74(s, 1H), 7.54(t, 
J=8.0Hz, 1H), 7.36(d, J=7.2Hz, 1H), 7.07(s, 1H), 6.53(s, 1H), 6.50(dd, J=10.0, 16.8Hz, 1H), 6.29(dd, 
J=2.0, 16.8Hz, 1H), 6.02(br s, 1H), 5.79(dd, J=2.0, 10.0Hz, 1H), 3.78(s, 3H), 3.07(m, 4H), 2.55(m, 
4H), 2.31(s, 3H). HRMS (ESI): exact mass calcd for C29H29N9O3 [M + H] +, 552.2466, found 
552.2460. HPLC analysis: 85:15 methanol−water, 6.02 min, 97.8%. 
 
tert-butyl(3-(2-((3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)oxy)-5-oxobenzo[4,5]imidazo[1,2-a]pyrimi
do[4,5-d]pyrimidin-12(5H)-yl)phenyl)carbamate (9e) 
A mixture of 7 (364mg, 1mmol), HATU (760.4mg, 2mmol) and diisopropyl-ethyl amine 
(0.522ml, 3mmol) in DCM (10 mL) was stirred for 0.5 h at room temperature, then 
2-chloro-1H-benzo[d]imidazole (152.5mg, 1mmol) was added to the mixture. The reaction mixture 
was stirred for 24 hrs at room temperature. The precipitate formed was collected by filtration and 
washed successively with DCM (5 mL), methanol (2 mL), water (5mL) to give 9e as a light yellow 
solid (270mg, 48%). 1H NMR (400Hz, DMSO- d6) δ 9.80 (s, 1H), 9.61 (s, 1H), 8.74 (d, J=3.6Hz, 1H), 
8.42 (d, J=7.6Hz, 1H) 7.99 (s, 1H) , 7.84 (d, J=8.0Hz, 1H), 7.64-7.68 (m, 3H), 7.59 (dd, J=4.4Hz, 
8.4Hz, 1H), 7.42-7.50 (m, 2H), 7.29-7.30 (m, 1H), 1.43 (s, 9H). 
 
12-(3-aminophenyl)-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)benzo[4,5]imidazo[
1,2-a]pyrimido[4,5-d]pyrimidin-5(12H)-one (10e) 
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To a solution of compound 9e (323.8mg, 0.5mmol) in tert-Butanol (5 mL) were added 2 
-methoxy-4-(4-met hylpiperazin-1-yl)aniline (110.6mg , 0.5 mmol) and potassium carbonate 
(207.3mg, 1.5mmol). The reaction mixture was stirred for 24 hrs at 110 ° C in a sealed tube，then the 
solvent was removed under reduced pressure. The residue was partitioned between water and 
dichloromethane. The organic layer was washed with brine, dried over MgSO4, and concentrated to 
give the crude product which was used without further purification.  
To a mixture of the crude product in dichloromethane (2 mL) was added trifluoroaceticacid 
(TFA) (2mL). The reaction mixture was stirred overnight at room temperature. The solvent was 
removed under reduced pressure, and neutralized the residue by slow addition of saturated NaHCO3. 
The precipitate formed was collected by filtration and washed with water. The resulting crude product 
was purified by silica gel chromatography with dichloromethane/methanol (60/1 to 30/1, v/v) to give 
10e as a yellow solid (82.1mg, 30%). 1H NMR (400Hz, CDCl3) δ 9.20(s, 1H), 8.49(d, J=8.0Hz, 1H), 
8.16(s, 1H), 7.65-7.69(m, 2H), 7.45(t, J=8.0Hz, 1H), 7.34-7.41(m, 2H), 6.95(d, J=8.8Hz, 1H), 6.90(d, 
J=7.6Hz, 1H), 6.80(s, 1H), 6.47(d, J=2.0Hz, 1H), 6.21(d, J=6.8Hz, 1H), 3.86-3.89(m, 5H), 3.15(m, 
4H), 2.60(t, J=5.2Hz, 4H), 2.38(s, 3H). 
 
N-(3-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxobenzo[4,5]imidazo[1,2-a]pyr
imido[4,5-d]pyrimidin-12(5H)-yl)phenyl)acrylamide (3e). 
Compound 3e was synthesized from 10e with similar procedures to that of 3a. 1H NMR (400Hz, 
DMSO- d6) δ 10.43(s, 1H), 9.00-9.09(m, 1H), 8.74(s, 1H), 8.35(d, J=7.2Hz, 1H), 7.89-7.95(m, 2H), 
7.56-7.60(m, 2H), 7.27-7.40(m, 4H), 6.52(s, 1H), 6.50(dd, J=10.0, 16.8 Hz, 1H), 6.29(dd, J=1.6, 
16.8H, 1H), 6.01(d, J=6.0Hz, 1H), 5.79(dd, J=1.6, 10.0Hz, 1H), 3.78(s, 3H), 3.04-3.13(m, 4H), 
2.44(m, 4H), 2.23(s, 3H). HRMS (ESI): exact mass calcd for C33H31N9O3 [M + H] +, 602.2623, found 
602.2615. Anal. Calcd. For C33H31N9O3·3/2H2O: C, 63.05; H, 5.45; N, 20.05; found: C, 63.10; H, 
5.40; N, 19.97. 
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N-(3-(2-((2-methoxy-4-morpholinophenyl)amino)-5-oxoimidazo[1,2-a]pyrimido[4,5-d]pyrimidin-
10(5H)-yl)phenyl)acrylamide(3f) 
Compound 3f was synthesized from 10f with similar procedures to that of 3a. 1H NMR (400Hz, 
DMSO- d6) δ 10.41(s, 1H), 9.07(s, 1H), 8.72(s, 1H), 7.89(m, 1H), 7.83(s, 1H), 7.75(s, 1H), 7.54(t, 
J=8.0Hz, 1H), 7.36(d, J=8.0Hz, 1H), 7.23(d, J=7.6Hz, 1H), 7.08(s, 1H), 6.54(s, 1H), 6.49(dd, J=10.0, 
16.8Hz, 1H), 6.29(dd, J=1.6, 16.8Hz, 1H), 6.02(d, J=7.6Hz, 1H), 5.79(dd, J=2.0, 10.0Hz, 1H), 
3.71-3.78(m, 7H), 3.01(m, 4H). HRMS (ESI): exact mass calcd for C28H26N8O4 [M + H] +, 539.2150, 
found 539.2154. HPLC analysis: 90:10 methanol−water, 4.28 min, 95.2%. 
 
N-(3-(2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-5-oxoimidazo[1,2-a]pyri
mido[4,5-d]pyrimidin-10(5H)-yl)phenyl)acrylamide (3g) 
Compound 3g was synthesized from 10g with similar procedures to that of 3a. 1H NMR (400Hz, 
Acetic acid-d4) δ 9.20(s, 1H), 8.17(d, J=7.6Hz, 1H), 7.80-7.82(m, 2H), 7.61-7.67(m, 2H), 7.33(d, 
J=7.6Hz, 1H), 7.23(m, 1H), 6.93(s, 1H), 6.46-6.47(m, 3H), 5.82(t, J=5.6Hz, 1H), 3.88(s, 3H), 
3.78-3.81(m, 2H), 3.63(t, J=11.2Hz, 1H), 3.16(t, J=11.2Hz, 2H), 2.92(s, 6H), 2.28-2.31(m, 2H), 
2.16-2.19(m, 2H). HRMS (ESI): exact mass calcd for C31H33N9O3 [M + H] +, 580.2779, 
found580.2787. HPLC analysis: 90:10 methanol−water, 10.09 min, 98.0%. 
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N-(3-(2-((2-ethoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-oxoimidazo[1,2-a]pyrimido[4,5-d]
pyrimidin-10(5H)-yl)phenyl)acrylamide (3h) 
Compound 3h was synthesized from 10h with similar procedures to that of 3a. 1H NMR (400Hz, 
DMSO- d6) δ 10.42(s, 1H), 9.07(s, 1H), 8.58(s, 1H), 7.91-7.92(m, 1H), 7.84(s, 1H), 7.75(s, 1H), 7.54(t, 
J=8.0Hz, 1H), 7.37-7.39(m, 1H), 7.24(d, J=8.4Hz, 1H), 7.08(s, 1H), 6.51(s, 1H), 6.49(dd, J=10.0, 
16.8Hz, 1H), 6.28(dd, J=1.6, 16.8Hz, 1H), 5.98-6.00(m, 1H), 5.79(dd, J=2.0, 10.0Hz, 1H), 
4.00-4.04(m, 2H), 3.02(m, 4H), 2.43(m, 4H), 2.22(s, 3H), 1.33(m, 3H). HRMS (ESI): exact mass 
calcd for C30H31N9O3 [M + H] +, 566.2623, found 566.2627. HPLC analysis: 90:10 methanol−water, 
5.40 min, 99.3%. 
In Vitro Enzymatic Activity Assay 
The Z’-LYTE™ biochemical assay employs a FRET-based, coupled-enzyme format and is based 
on the differential sensitivity of phosphorylated and non-phosphorylated peptides to proteolytic 
cleavage (Figure S1). The recommended excitation wavelength is 400 nm and the recommended 
emission wavelengths are 445 nm and 520 nm, respectively. The Emission Ratio is calculated by the 
equation below. This Kit provides a screening assay that yields Z’-factor values >0.7. 
Emission Ratio = C୭୳୫ୟ୰୧୬ E୫୧ୱୱ୧୭୬ ሺସସହ ୬୫ሻF୪୳୭୰ୣୱୡୣ୧୬ E୫୧ୱୱ୧୭୬ ሺହଶ଴ ୬୫ሻ 
 
Figure S1. Schematic diagram of the Z’-LYTE™ biochemical assay (Invitrogen) 
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The concentrations of different kinase were determined by optimization experiments and the 
respective concentration was: EGFR-T790M (PV4803, Invitrogen) 0.174μg/μL, 
EGFR-L858R/T790M (PV4879, Invitrogen) 0.055μg/μL. The compounds were diluted three-fold 
from 5.1x10-9 M to 1x10-4 M in DMSO. Plate was measured on EnVision Multilabel Reader (Perkin 
Elmer). Curve fitting and data presentations were performed using Graph Pad Prism version 4.0. 
Every experiment was repeated at least 3 times. 
Western Blotting 
1x106 cells of H1975 were seed into 6-cm dishes. 24 hrs latter, medium was changed and 2.0, 0.4, 
0.08, 0.016μM of 3d/3g was added. Medium with 1‰ DMSO was used as control. Cells were exposed 
to treatment for 2 hrs. Washed the dishes twice using pre-cold PBS, removed the residuary PBS 
completely, and 400 μL 1x Cell Lysis Buffer was added. The lysis buffer was prepared according to 
CST protocol. After incubating plates on ice for 5 minutes, cells were scraped carefully and sonicated 
immediately. Centrifuged extract for 10 minutes at 14,000 x g at 4 ˚С, remained the supernatant and 
denatured it via boiling. Samples were maintained at -70˚С. 20L sample was loaded. Proteins were 
transfered to PVDF membrane (Mili pore). PVDF membranes were blocked in 5% bovine serum 
albumin-TBST for 1h. The primary antibody EGFR (CST, 2232), phospho-EGFR (Tyr1068) (CST, 
2234), AKT (CST, 9272), phospho-AKT (Ser 473) (CST, 9271), ERK (CST, 9102), phospho-ERK 
(t202/y204) (CST, 9101), GAPDH (KC-5G5, KangChen) were dilute 1:1000 with 5% BSA-TBST to 
use. The membrane was incubated in primary antibody for 2 hours at room temperature. Wash 
membrane three times for 10 minutes each with TBST. the membrane was incubated for 1h at room 
temperature with horseradish peroxidase (HRP, sigma) conjugated Rabbit secondary antibody, diluted 
to 1:2000 in 5% BSA-TBST. Wash membrane three times for 10 minutes each with TBST. Blots were 
developed by enhanced chemiluminescence (Thermo). 
For selectivity assay, NCI-H820 (NSCLC, EGFR del E746-E749/T790M),NCI-H446, NCI-H322, 
NCI-H1703, NCI-H1299, A549, 95D, NCI-H358, NCI-H661(NSCLC, EGFRWT) cells were exposed 
to 0.5 μM of 3d/3g for 2 hrs,and then excited 0.5 hr with EGF(200ng/mL), and then excited 0.5 hr 
with EGF (200ng/mL) western blot was performed and pEGFR(Y1068) was tested, α-Tubulin was 
used as control. 
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Figure S2. Compounds 3d/3g shows low potency to inhibit the activation of EGFR in cancer cells 
with wide type EGFR. 
Cell Proliferation and Growth Inhibition Assay 
NCI-H1975, NCI-H322, A549, NCI-H1299, NCI-H1703, NCI-H661, 95D, NCI-H358, HCC827,  
HLF-1, HL-7702，A431 cells were cultured with respective growth medium. Before use, cells were at 
least passaged twice after thawing. Cells of log phase were trypsinized and resuspended in growth 
medium. 1000-3000 cells/well were seeded in 96-well plates with a 100 μL volume, 6 parallels and 7 
rows were designed.  Plates were maintained at 37  in a 5% CO℃ 2 incubator overnight. Dissolved 
the compounds with DMSO to 10μM, and a five-fold serial dilution of the compounds from 1x10-5 M 
to 0.64x10-9 M was performed (10 μL compound solution plus 90 μL DMSO). 2μl of compound 
solution was added to 998 μL growth medium, the mixture was vortexes sufficiently. 100 μL mixture 
was correspondingly added to 96-well plate. 2 μL DMSO instead of compound solution was used as 
0% inhibitor control. After co-incubation for 68 hrs, 20 μL MTT (5mg/ml) was added. 4hs later, 
discarded supernatant completely and added 150μL DMSO. After shaking for 10 min, the plates were 
read in the Synergy™ HT (Bio Tek) at 570nm. The data was calculated using Graph Pad Prism 
version 4.0. The IC50 were fitted using a non-linear regression model with a sigmoidal dose response. 
Table S1. Antiproliferative activities of the new inhibitors 3 against cells Harboring different status of 
EGFR. [a] 
[a] The antiproliferative activities of the compounds were evaluated using the MTS assay. The data 
were means from at least four independent experiments. 
Cpds 
IC50(μM) 
HCC827 H1975 A431 A549 HL-7702 
3a 0.033±0.011 1.107±0.343 2.656±1.423 12.012±3.716 35.058±5.947 
3b 0.057±0.016 3.556±1.165 23.066±8.543 52.968±9.992 37.895±5.595 
3c 0.019±0.006 0.648±0.081 1.536±0.693 7.129±2.850 9.128±1.676 
3d 0.039±0.013 0.143±0.026 2.983±1.115 12.417±2.166 9.963±5.080 
3e 0.023±0.008 0.307±0.089 3.567±0.373 3.132±1.373 3.230±0.423 
3f 0.142±0.061 0.476±0.219 >30 >30 >30 
3g 0.049±0.027 0.086±0.018 14.53±8.105 >30 >30 
3h 0.046±0.0162 0.396±0.179 5.254±3.482 4.478±2.54 5.46±3.735 
WZ4002 0.009±0.001 0.055±0.011 1.042±0.014 4.069±1.755 21.425±5.915 
Gefinitib 0.005±0.002 13.125±0.925 1.199±0.473 17.091±6.37 11.840±2.533 
S14 
 
Cell Cycle Assay 
H1975 cells were plated in 6-well plates overnight. Medium of none FBS was used for 
synchronization. 24 hrs latter, growth medium with 3d/3g (0.01μM, 0.1μM, 1μM) were changed. 
Medium with 1‰ DMSO was used as control. After incubated for 24 hrs, cells were collected and 
centrifuged for 10 minutes at 300 x g. The samples were washed twice with washing buffer, discarded 
the supernatant completely. Cells were treated with 250μl solution A and 200 μL solution B for 10min 
respectively; 250μL PI (solution C) was added in the end (CYCLETEST PLUS DNA REAGENT KIT, 
BD Pharmingen). After 10 min staining, cell suspension was filtered via 200 mesh Filter mesh. 
Samples were analyzed on a FACS Calibur flow cytometer (Becton Dickinson), and Data were 
analyzed using the Modfit software package. 
 
Figure S3. Compounds 3d/3g dose-dependently induces G1/S arrest of NCI-H1975 NSCLC cells.  
Cell Apoptosis Assay 
H1975 cells were plated in 6-well plates overnight. Fresh growth medium with 3d/3g (0.1μM, 
0.5μM, 1μM) was added. Medium with 1‰ DMSO was used as control. After incubating for 24 hrs, 
growth medium was collected and cells were trypsined and collected correspondingly to the medium. 
Suspensions were centrifuged for 10 minutes at 300 x g at 4 ˚С. Removed the supernatant completely 
and washed cells twice with pre-cold PBS. 200μL 1 x Binding buffer and 2.5μL 7-AAD, 2.5 μL 
annexin-V were added (PE-Annexin V Kit,BD Pharmingen). Gently vortex the cells and incubate for 
15 min at rt (25 °C) in the dark. Cells stained with 7-AAD, annexin-V alone were used as positive 
control. The samples were detected with FACS Calibur flow cytometer (Becton Dickinson).  
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Figure S4. Compounds 3d/3g dose-dependently induces NCI-H1975 NSCLC cell apoptosis. 
Colony Formationassay 
H1975 cells were cultured in RPMI 1640, supplemented by 10% FBS. Cells were passaged prior 
to achieving full confluence. Washed the cell twice with PBS, lifted by adding 1ml trypsin and 
incubated for 2 minutes at 37 ºC. The cell suspension was spun down in a centrifuge for 10 minutes at 
500xg and was resuspended in 5 ml of culture medium. The concentration determined by counting 
using a haemocytometer. A cell suspension of 500 cells/3ml was performed by adding suitable growth 
medium. 3ml cell suspension was plated into a 6-cm dish. 4 parallels and 7 gradients were set. 3 L 
different concentration (10μM, 1μM, 0.1μM, 0.01μM, 0.001μM, 0.0001μM) of compounds 3d/3g 
dissolved in DMSO was added immediately. Plates with 1‰ DMSO added were used as control. 
Medium with 3d/3g was changed every 3 days. 9 days later, the colonies were mainly greater than 50 
cells. Removed suspension and wash the plates twice with PBS. 4% formaldehyde was used to fix the 
colonies for 10 min, washed twice with PBS, and stained the plates with 0.2% crystal violet for 10 min. 
Wash the plates with PBS until the background is clear. The plates were scanned with a HP scanner. 
The data was calculated using Graph Pad Prism version 4.0. The IC50 were calculated by using a 
non-linear regression model with a sigmoidal dose response. 
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Figure S5. Compounds 3d/3g inhibited the colony formation of NCI-1975 NSCLC cells in a dose 
dependent manner. 
Cell Migration and Invasion Assay 
Wound healing assay was used to evaluate the inhibitory effect on H1975 cell migration ability 
of 3d/3g. Cells were plated 90% confluence overnight and scratched with a tip, 3d/3g (50, 250nM) 
was added immediately. The scratch length at 0 h and 24 hrs was measured after microscopic 
photograph was taken and the migration ratio was set as 0 h/24 hrs. Trans-Well assay was also used, 
6x104 NCI-H1975 cells were plated in Trans-Well chamber, incubated 24 hrs with 3d/3g (50, 250nM), 
cells were fixed and dyed and micrographs were taken. Cell number passed through was counted and 
column graph was made. In invasion assay, MaxGel™ ECM (Sigma, E0282) was used to simulate the 
extra-cellular matrix. 
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Figure S6. Compounds 3d/3g inhibited the migration and invasion of NCI-1975 NSCLC cells in dose 
dependent manners. (a) Wound healing assay on NCI-H1975 cell. (b) Trans-well (migration) assay on 
NCI-H1975 cell. (c) Trans-well (invasion) assay on NCI-H1975 cell. (d) Statistical analysis of the 
results. 
Kinase Profiling Results 
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Figure S7. Kinase profiling results performed by using the Ambit Kinome screening platform. The 
Ambit score is calculated as the percent of DMSO control. XTF-150 : 3g. S = Number of hits / Number 
of assays, S(35) = (number of non-mutant kinases with %Ctrl <35)/(number of non-mutant kinases 
tested), S(10) = (number of non-mutant kinases with %Ctrl <10)/(number of non-mutant kinases 
tested), S(1) = (number of non-mutant kinases with %Ctrl <1)/(number of non-mutant kinases tested). 
 
 
Figure S8. KINOMEsacn tree spot maps illustrating the selectivity profiles for compounds 3g versus a 
panel of 456 kinase targets (including 395 wild-type kinases). The size of the red circle is proportional 
to the percent of DMSO control, where 0% and 35% of control equals 100% and 65% competition, 
respectively. 
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NAME           13.02.20
EXPNO               560
PROCNO                1
Date_          20130102
Time              16.49
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                   16
DS                    2
SWH            8278.146 Hz
FIDRES         0.126314 Hz
AQ            3.9584243 sec
RG                322.5
DW               60.400 usec
DE                 6.50 usec
TE                296.8 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                12.58 usec
PL1                0.00 dB
PL1W        10.87646866 W
SFO1        400.1324710 MHz
SI                32768
SF          400.1300020 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
XTF-16
N
N N
N
N
O
NH
HN
N
O
O
N 3h
